Pharvaris (PHVS)
(Delayed Data from NSDQ)
$18.77 USD
-0.22 (-1.16%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $18.87 +0.10 (0.53%) 6:54 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Pharvaris N.V. [PHVS]
Reports for Purchase
Showing records 1 - 20 ( 22 total )
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
Big Splash At Bradykinin Symposium As PHVS Rolls Out Additional Data
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
Moving On To The Next Chapter As PHVS Reaches Alignment On Pivotal Design
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
Pushing Forward With Deucrictibant In Important Year Of Execution
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
Addition To The C-Suite As Deucrictibant Progress Continues
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
Moving With RAPID(e-3) Speed: Thoughts on On-Demand Phase 3 Study
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
KONFIDENT Read Through: Thoughts on PHVS'' Deucrictibant
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
Biotechnology- HAE KOL Call Check: Revisiting The Therapeutic Landscape
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
INVITE: HAE KOL Call -- Revisiting the HAE Treatment Landscape
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
Nothing Holding Them Back -- FDA Lifts Clinical Hold On Deucrictibant
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
Moving On To The Next CHAPTER With Successful Phase 2 Prophy Data
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
Company: Pharvaris N.V.
Industry: Medical - Biomedical and Genetics
Starting The Next CHAPTER(-1) By YE23; Looking Ahead To Additional Updates
Provider: Wedbush Securities Inc.
Analyst: CHICO L